Patents Assigned to Medicinal Bioconvergence Research Center
  • Patent number: 11029504
    Abstract: Disclosed are a window apparatus for obtaining a microscopic image of in vivo breast tissue and a method for using the window apparatus to obtain cell-level and molecular-level microscopic images of in vivo breast tissue while maintaining the biological environment of the in vivo breast tissue. In one embodiment, a window apparatus comprises a first chamber having a ring structure with an open window on the center, and a cover glass disposed on the upper part and breast tissue placed on the lower part; a second chamber having an opening window on the center coupled to the first chamber to support the breast tissue; and a chamber holder for fixing the first and second chambers having a tilting mount placing unit with the tilting mount placed to have the cover glass and an object lens of a confocal microscope system stay parallel to each other.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: June 8, 2021
    Assignees: MEDICINAL BIOCONVERGENCE RESEARCH CENTER, KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Pil Han Kim, Yeseul Kim, Inwon Park, Sunghoon Kim
  • Patent number: 10677806
    Abstract: A method for diagnosing follicular thyroid carcinoma is described. The method measures protein expression levels of an aminoacyl-tRNA synthetase (ARS) or an aminoacyl-tRNA synthetase complex-interacting multifunctional protein (AIMP) in a sample, such as a thyroid tissue sample, from a subject suspected of having follicular thyroid carcinoma. The protein expression levels of ARS or AIMP are compared to the measured protein expression levels in a control.
    Type: Grant
    Filed: December 27, 2018
    Date of Patent: June 9, 2020
    Assignees: MEDICINAL BIOCONVERGENCE RESEARCH CENTER, THE ASAN FOUNDATION, UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION
    Inventors: Sunghoon Kim, Won Suk Yang, Kyunggon Kim, Won Gu Kim
  • Patent number: 10646547
    Abstract: A polypeptide having chemokine activity mediated by binding to C-C chemokine receptor type 3 (CCR3) comprising SEQ ID NO: 1 and uses thereof are described.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: May 12, 2020
    Assignee: MEDICINAL BIOCONVERGENCE RESEARCH CENTER
    Inventors: Sunghoon Kim, Min Chul Park, Byung Woo Han, Joon-Sung Park
  • Publication number: 20190321455
    Abstract: The present invention relates to an EPRS (glutamyl-prolyl-tRNA synthetase) protein or a fragment thereof. The EPRS protein of the present invention or fragment thereof may bind to PCBP2 protein to activate the MAVS signaling pathway, and thus it has anti-RNA viral effects, thereby being effective for preventing or treating a RNA viral infectious disease.
    Type: Application
    Filed: February 22, 2019
    Publication date: October 24, 2019
    Applicants: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY, MEDICINAL BIOCONVERGENCE RESEARCH CENTER
    Inventors: Myung Hee Kim, Eun Young Lee, Sung Hoon Kim, Chul Ho Lee
  • Patent number: 10437035
    Abstract: Disclosed are a microaspiration-based lung window apparatus for obtaining a microscopic image of in vivo lung tissue and a method for using the window apparatus to obtain cell-level and molecular level microscopic images of in vivo lung tissue while maintaining physiological respiration and circulation of an animal without interference. In one embodiment, a lung window apparatus comprises an open window having the upper and lower parts open, a cover glass placed over the upper part and lung tissue coming in contact with the lower part; an aspiration tube extending from one side of the open window to an aspiration apparatus enabling the inside of the open window to be in a vacuum state; and a tilting mount placing unit extending from one side of the open window having a tilting mount to enable the cover glass and an object lens of a confocal microscope system to stay parallel to each other.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: October 8, 2019
    Assignees: Medicinal Bioconvergence Research Center, Korea Advanced Institute of Science and Technology
    Inventors: Pil Han Kim, Inwon Park, Sunghoon Kim
  • Patent number: 10258674
    Abstract: The present invention relates to nanoparticles comprising aminoacyl tRNA synthetase and an anticancer composition comprising the same and, specifically, to nanoparticles which comprise glycyl-tRNA synthetase (GRS), leucyl-tRNA synthetase (LRS), and isoleucyl-tRNA synthetase (IRS), and have anticancer or immunostimulating activity; a pharmaceutical composition for preventing or treating cancer, comprising the nanoparticles as an active ingredient; a composition for immunostimulation; and a method for preparing the nanoparticles.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: April 16, 2019
    Assignee: MEDICINAL BIOCONVERGENCE RESEARCH CENTER
    Inventors: Sunghoon Kim, Min Chul Park
  • Publication number: 20190039064
    Abstract: Provided is a bio chip structure for a comparative experiment. The bio chip structure for a comparative experiment according to the present invention may include: a first pillar substrate including at least one first pillar where a first sample is disposed; a second pillar substrate including at least one second pillar where a second sample is disposed; and a well substrate including wells to which at least one pair of the first pillars of the first pillar substrate and the second pillar of the second pillar substrate is inserted. Accordingly, a comparative experiment to culture a different kind of samples may be conducted in an identical environment, a different kind of samples, which are the subjects of a comparative experiment, may be rapidly and accurately disposed on a plurality of pillars, and an experimental group or a control group may be easily replaced.
    Type: Application
    Filed: August 9, 2017
    Publication date: February 7, 2019
    Applicants: MBD KOREA. CO., LTD., MEDICINAL BIOCONVERGENCE RESEARCH CENTER
    Inventors: Dong Woo LEE, Chan Ho PARK, Sung Hoon KIM
  • Publication number: 20190016790
    Abstract: The present invention relates to an antibody specifically binding to PICP or a fragment thereof; an enzyme-linked immunosorbent assay (ELISA) kit and a composition for diagnosing metabolic bone diseases, both of which contain the same; a method for detecting PICP by using the same; a polynucleotide encoding the antibody or a fragment, and a recombinant expression vector comprising the same; cells transformed by the recombinant expression vector; and a method for preparing an antibody specifically binding to PICP or a fragment thereof by using the recombinant expression vector, and a method for preparing a recombinant PICP protein.
    Type: Application
    Filed: December 30, 2016
    Publication date: January 17, 2019
    Applicant: MEDICINAL BIOCONVERGENCE RESEARCH CENTER
    Inventors: Sunghoon KIM, Woo-Young SEO, Sujin KANG, Yong-Sung KIM, Jeong-Ho KIM, Du-San BAEK
  • Patent number: 10139394
    Abstract: The present invention relates to a novel function of lysyl tRNA synthetase, that is, lysyl tRNA synthetase interacts with 67LR through translocation of KRS into plasma membrane, and so enhances tumor (or cancer) cell migration, thereby having an effect on cancer metastasis. More specifically, it relates to method for controlling cancer metastasis or cancer cell migration by modulating an cellular level of lysyl tRNA synthetase, an use of an expression vector comprising a construct inhibiting KRS expression for preventing or treating cancer, an use of an agent inhibiting KRS activity for preventing or treating cancer, a method for screening an agent which modulates cancer metastasis or cancer cell migration, a method for screening an agent inhibiting an interaction between KRS and 67LR. Accordingly, cancer metastasis and cancer cell migration may be controlled using the inventive KRS, further the cellular metabolism related to laminin receptor (67LR) of plasma membrane may be controlled.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: November 27, 2018
    Assignee: MEDICINAL BIOCONVERGENCE RESEARCH CENTER
    Inventors: Sunghoon Kim, Jin Woo Choi
  • Patent number: 10130611
    Abstract: This application relates to a novel benzo-heterocycle derivative and more particularly, it relates a composition for preventing and treating cancer or for inhibiting metastasis comprising benzo-heterocycle derivative or pharmaceutically acceptable salts thereof as an active ingredient. The present inventors confirmed that KRS has an effect on cancer metastasis by facilitating cancer (or tumor) cell migration through interaction with 67LR, and also found that a substance inhibiting the interaction between KRS and 67LR can prevent and treat cancer by inhibiting cancer cell metastasis. Accordingly, the composition of the present invention can inhibit cancer metastasis, and thus provide a novel means for prevention and treatment of cancer.
    Type: Grant
    Filed: May 7, 2012
    Date of Patent: November 20, 2018
    Assignee: MEDICINAL BIOCONVERGENCE RESEARCH CENTER
    Inventors: Sunghoon Kim, Jin Woo Choi, Jin Young Lee, Dae Gyu Kim, Gyoon Hee Han, Jee Sun Yang, Chul Ho Lee
  • Publication number: 20180246311
    Abstract: Disclosed are a microaspiration-based lung window apparatus for obtaining a microscopic image of in vivo lung tissue and a method for using the window apparatus to obtain cell-level and molecular level microscopic images of in vivo lung tissue while maintaining physiological respiration and circulation of an animal without interference. In one embodiment, a lung window apparatus comprises an open window having the upper and lower parts open, a cover glass placed over the upper part and lung tissue coming in contact with the lower part; an aspiration tube extending from one side of the open window to an aspiration apparatus enabling the inside of the open window to be in a vacuum state; and a tilting mount placing unit extending from one side of the open window having a tilting mount to enable the cover glass and an object lens of a confocal microscope system to stay parallel to each other.
    Type: Application
    Filed: August 31, 2016
    Publication date: August 30, 2018
    Applicant: Medicinal Bioconvergence Research Center
    Inventors: Pil Han KIM, Inwon PARK, Sunghoon KIM
  • Patent number: 9945859
    Abstract: The present invention relates to an anti-lysyl-tRNA synthetase (KRS) antibody selectively binding to KRS, and a use thereof and, more specifically, to an antibody binding to human KRS or a fragment thereof, a method for producing the same, and a composition containing the same for diagnosing cancer, autoimmune diseases or inflammatory diseases. The antibody or fragment thereof of the present invention specifically binds to human KRS, and enables KRS detection and inhibition due to the absence of cross-linkage reactivity with the other proteins including the same ARS family, and thus the antibody or fragment thereof can be used to detect KRS and diagnose KRS-related diseases, i.e., cancer, autoimmune diseases or inflammatory diseases.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: April 17, 2018
    Assignee: MEDICINAL BIOCONVERGENCE RESEARCH CENTER
    Inventors: Sunghoon Kim, Yon-Sik Choi, Hyunbo Shim, Nam Ju Lee, Min Hwa Park
  • Patent number: 9944713
    Abstract: Described herein are an antibody specifically binding to AIMP2-DX2 protein, and a diagnostic kit for detecting cancer which comprises the antibody specific to the AIMP2-DX2.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: April 17, 2018
    Assignee: Medicinal Bioconvergence Research Center
    Inventors: Sunghoon Kim, Jin Woo Choi
  • Patent number: 9539236
    Abstract: Exemplary embodiments relate to a novel anticancer composition including a compound represented by chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient:
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: January 10, 2017
    Assignee: Medicinal Bioconvergence Research Center
    Inventors: Sunghoon Kim, Nam Hoon Kwon, Dae Gyu Kim
  • Patent number: 9511085
    Abstract: The present invention relates to a novel function of lysyl tRNA synthetase (KRS) which enhances tumor cell migration and affects cancer metastasis via KRS's interaction with laminin receptor (67LR) by its translocation to membrane. More particularly, the present invention relates to a method for modulating cancer metastasis or migration, which comprises regulating intracellular levels of KRS; a composition for preventing or treating cancer; use of expression vector for inhibiting the expression of KRS; a method for preventing or treating cancer; use of an agent for inhibiting an activity of KRS; a method for screening an agent which modulates cancer metastasis or migration; and a method for screening an agent which inhibits the interaction of KRS with 67LR, by said novel function. Thus, KRS can modulate cancer metastasis or migration and furthermore, can modulate intracellular metabolism related to 67LR.
    Type: Grant
    Filed: August 18, 2008
    Date of Patent: December 6, 2016
    Assignee: Medicinal Bioconvergence Research Center
    Inventors: Sunghoon Kim, Jin Woo Choi
  • Patent number: 9435807
    Abstract: Provided is a method of screening for agents for preventing or treating mTORC 1 mediated diseases by screening test agents to determine test agents that inhibit the binding ability of LRS to RagD, or RagD GTPases, and a method of reducing cell size as compared to the control group, including inhibiting the expression of intracellular LRS in the cells.
    Type: Grant
    Filed: March 24, 2014
    Date of Patent: September 6, 2016
    Assignee: Medicinal Bioconvergence Research Center
    Inventors: Sunghoon Kim, Jung Min Han
  • Patent number: 9274113
    Abstract: The present invention relates to a novel method of screening an agent for preventing or treating cancer using glycyl-tRNA synthetase (GRS) and cadherin (CDH). More particularly, it relates to a method of screening and test agent which modulates the binding level of GRS or their fragment with CDH. As can be seen foregoing, the present invention relates to a novel use of GRS and CDH and provides a method of screening an agent for preventing or treating cancer. The method may be used for developing novel agent for treatment of various cancer.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: March 1, 2016
    Assignee: Medicinal Bioconvergence Research Center
    Inventors: Sunghoon Kim, Min Chul Park
  • Patent number: 9206132
    Abstract: An aminopyridine derivative of Formula 1 and a method of preventing or treating cancer using the same. Formula 1: In Formula 1: X1 and X2 are each independently selected from the group consisting of carbon and nitrogen; R1 to R5 are each independently selected from the group consisting of a hydrogen, a straight, a branched, or cyclo alkyl of C1-C4, a halogen, and a hydroxyl; and R6 is a hydrogen or an alkyl of C1-C6.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: December 8, 2015
    Assignee: Medicinal Bioconvergence Research Center
    Inventors: Sunghoon Kim, Hee Sook Lee, Young Sun Oh, Dae Gyu Kim
  • Publication number: 20140249045
    Abstract: Provided is a method of screening for agents for preventing or treating mTORC1 mediated diseases by screening test agents to determine test agents that inhibit the binding ability of LRS to RagD, or RagD GTPases, and a method of reducing cell size as compared to the control group, including inhibiting the expression of intracellular LRS in the cells.
    Type: Application
    Filed: March 24, 2014
    Publication date: September 4, 2014
    Applicant: Medicinal Bioconvergence Research Center
    Inventors: Sunghoon KIM, Jung Min Han
  • Publication number: 20140220596
    Abstract: The present invention relates to a novel method of screening an agent for preventing or treating cancer using glycyl-tRNA synthetase (GRS) and cadherin (CDH). More particularly, it relates to a method of screening and test agent which modulates the binding level of GRS or their fragment with CDH. As can be seen foregoing, the present invention relates to a novel use of GRS and CDH and provides a method of screening an agent for preventing or treating cancer. The method may be used for developing novel agent for treatment of various cancer.
    Type: Application
    Filed: April 10, 2014
    Publication date: August 7, 2014
    Applicant: Medicinal Bioconvergence Research Center
    Inventors: Sunghoon KIM, Min Chul Park